Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2013

View Archived Issues

A prognostic peptide-based signature for end-stage renal disease in fetal urinary output

Medimmune to acquire Amplimmune

AiCuris presents a novel class of antibacterial compound with potent activity

An oral multikinase inhibitor shows potent antiangiogenic activity in vivo

Carolus and TAP seek to validate RANTES:Pf-4 as CT-2009 target

Acucela's SEATTLE study reaches half way enrollment

TRPM8 blockade as a potential new treatment strategy for urinary bladder disorders

Licensing and codevelopment agreement for NovaBiotics' first-in-class antifungal peptide

Lee's Pharmaceutical submits CTA to expand the APEX study to China

Orexo updates on OX-51 phase II dose-finding study

Arena Pharmaceuticals completes phase Ib APD-811 trial

FDA accepts for review dabigatran supplemental NDA

U.K.'s NICE does not recommend everolimus use by NHS

Cepheid's Xpert MTB/RIF test categorized by FDA

The University of Virgina presents new sphingosine kinase inhibitors

Novel EGFR inhibitors disclosed by Taiho Pharmaceutical

Scientists at Innate Pharma divulge new MAbs for cancer

Sunovion Pharmaceuticals discloses new antipsychotic agents

FDA extends PDUFA goal date for Xiaflex

Teva decides not to license RX-3117 from Rexahn

Japanese launch for Bonviva injection

Phase II trial planned for CF-102 in hepatocellular carcinoma

Daiichi Sankyo files marketing application for Ranmark in Japan

Grifols and Aradigm close worldwide licensing agreement for inhaled formulations of ciprofloxacin

Europe Commission approves Eylea for visual impairment complications following CRVO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...